{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:31:34Z","timestamp":1789007494305,"version":"build-2803163510"},"reference-count":181,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymthe.2026.06.030","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:32:05Z","timestamp":1781911925000},"page":"5103-5126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gene delivery for cerebral neurodegenerative disorders: Current advancements and limitations"],"prefix":"10.1016","volume":"34","author":[{"given":"Kunal","family":"Dayma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1675-1744","authenticated-orcid":false,"given":"Arun","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.06.030_bib1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/mthe.2001.0454","article-title":"Stanfield Rogers: insights into virus vectors and failure of an early gene therapy model","volume":"4","author":"Friedmann","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/ijabmr.IJABMR_190_19","article-title":"Onasemnogene Abeparvovec for Spinal Muscular Atrophy: The Costlier Drug Ever","volume":"9","author":"Mahajan","year":"2019","journal-title":"Int. J. Appl. Basic Med. Res."},{"key":"10.1016\/j.ymthe.2026.06.030_bib4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-Associated Defective Virus Particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.06.030_bib5","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1073\/pnas.55.6.1467","article-title":"Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics","volume":"55","author":"Hoggan","year":"1966","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.06.030_bib6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-Associated Virus (AAV) as a Vector for Gene Therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.ymthe.2026.06.030_bib7","article-title":"Gene Therapy: The Next-Generation Therapeutics and Their Delivery Approaches for Neurological Disorders","volume":"4","author":"Paul","year":"2022","journal-title":"Front Genome"},{"key":"10.1016\/j.ymthe.2026.06.030_bib8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1089\/hum.2012.229","article-title":"Biosafety features of lentiviral vectors","volume":"24","author":"Schambach","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2026.06.030_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10571-004-1374-y","article-title":"Dynamics of CNS barriers: evolution, differentiation, and modulation","volume":"25","author":"Abbott","year":"2005","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.ymthe.2026.06.030_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13052-018-0563-0","article-title":"Possible strategies to cross the blood-brain barrier","volume":"44","author":"Bellettato","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.ymthe.2026.06.030_bib13","series-title":"Anatomy, Head and Neck: Blood Brain Barrier","author":"Dotiwala","year":"2025"},{"key":"10.1016\/j.ymthe.2026.06.030_bib14","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a004911","article-title":"Basement membranes: cell scaffoldings and signaling platforms","volume":"3","author":"Yurchenco","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/svn-2018-000198","article-title":"Basement membrane and blood-brain barrier","volume":"4","author":"Xu","year":"2019","journal-title":"Stroke Vasc. Neurol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood-brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physrev.00050.2017","article-title":"Blood-Brain Barrier: From Physiology to Disease and Back","volume":"99","author":"Sweeney","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ymthe.2026.06.030_bib18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/jcm14020386","article-title":"The Crucial Role of the Blood-Brain Barrier in Neurodegenerative Diseases: Mechanisms of Disruption and Therapeutic Implications","volume":"14","author":"Kim","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib19","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1152\/physrev.00004.2013","article-title":"Cerebrospinal fluid secretion by the choroid plexus","volume":"93","author":"Damkier","year":"2013","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ymthe.2026.06.030_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12987-020-00196-2","article-title":"Choroid plexus and the blood-cerebrospinal fluid barrier in disease","volume":"17","author":"Sol\u00e1r","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.ymthe.2026.06.030_bib21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41578-021-00394-w","article-title":"Drug delivery to the central nervous system","volume":"7","author":"Nance","year":"2022","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ymthe.2026.06.030_bib22","article-title":"Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease","volume":"15","author":"Derk","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ymthe.2026.06.030_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00401-018-1809-z","article-title":"The meninges as barriers and facilitators for the movement of fluid, cells and pathogens related to the rodent and human CNS","volume":"135","author":"Weller","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/jnc.13861","article-title":"Trafficking of adeno-associated virus vectors across a model of the blood-brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells","volume":"140","author":"Merkel","year":"2017","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymthe.2026.06.030_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.ymthe.2026.06.030_bib27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","article-title":"Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain","volume":"11","author":"Pardridge","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ymthe.2026.06.030_bib28","article-title":"The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications","volume":"5","author":"Banks","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111571","article-title":"Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib","volume":"182","author":"Radaram","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ymthe.2026.06.030_bib30","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/00000542-199210000-00020","article-title":"Physical and chemical properties of drug molecules governing their diffusion through the spinal meninges","volume":"77","author":"Bernards","year":"1992","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ymthe.2026.06.030_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2026.06.030_bib32","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1159\/000110445","article-title":"TNF activates P-glycoprotein in cerebral microvascular endothelial cells","volume":"20","author":"Yu","year":"2007","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ymthe.2026.06.030_bib33","first-page":"19","article-title":"Immune cells: potential carriers or agents for drug delivery to the central nervous system","volume":"11","author":"Zhang","year":"2024","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.ymthe.2026.06.030_bib34","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1172\/JCI58644","article-title":"Innate immunity in the central nervous system","volume":"122","author":"Ransohoff","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.06.030_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00435","article-title":"Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference?","volume":"21","author":"Harkins","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymthe.2026.06.030_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.618020","article-title":"AAV Targeting of Glial Cell Types in the Central and Peripheral Nervous System and Relevance to Human Gene Therapy","volume":"13","author":"O\u2019Carroll","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ymthe.2026.06.030_bib37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.fmre.2023.01.012","article-title":"Skull and vertebral bone marrow in central nervous system inflammation","volume":"4","author":"Ren","year":"2024","journal-title":"Fundam. Res."},{"key":"10.1016\/j.ymthe.2026.06.030_bib38","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","article-title":"Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors","volume":"14","author":"Kruzik","year":"2019","journal-title":"Mol. Ther. - Methods Clin. Development"},{"key":"10.1016\/j.ymthe.2026.06.030_bib39","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","article-title":"Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial","volume":"75","author":"Rafii","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5413","article-title":"Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2","volume":"12","author":"Sondhi","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101643","article-title":"Inhibition of immune response reduces pathology in dorsal root ganglia and peripheral nerves in cynomolgus macaques following AAV gene therapy","volume":"33","author":"Grubor","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.06.030_bib42","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.06.030_bib43","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.4049\/jimmunol.1600757","article-title":"Selectivity of Human TLR9 for Double CpG Motifs and Implications for the Recognition of Genomic DNA","volume":"198","author":"Pohar","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib44","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.ymthe.2024.03.036","article-title":"An innate immune response to adeno-associated virus genomes decreases cortical dendritic complexity and disrupts synaptic transmission","volume":"32","author":"Suriano","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib46","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.omtm.2023.08.015","article-title":"Modifying immune responses to adeno-associated virus vectors by capsid engineering","volume":"30","author":"Bentler","year":"2023","journal-title":"Mol. Ther. - Methods Clin. Development"},{"key":"10.1016\/j.ymthe.2026.06.030_bib47","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2012-10-460733","article-title":"Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells","volume":"121","author":"Martino","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.06.030_bib48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.addr.2020.02.006","article-title":"Intrathecal drug delivery in the era of nanomedicine","volume":"165\u2013166","author":"Fowler","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2026.06.030_bib49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/17425240903540205","article-title":"Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics","volume":"7","author":"Soderquist","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ymthe.2026.06.030_bib50","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2014.210","article-title":"Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates","volume":"23","author":"Meyer","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib51","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200229","article-title":"Current Advances and Challenges in Gene Therapies for Neurologic Disorders: A Review for the Clinician","volume":"11","author":"Porcari","year":"2025","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.ymthe.2026.06.030_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115363","article-title":"Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications","volume":"211","author":"Ye","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2026.06.030_bib53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ymthe.2019.11.012","article-title":"A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna","volume":"28","author":"Taghian","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib54","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1186\/s12967-024-05661-2","article-title":"Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside","volume":"22","author":"Xu","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib55","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/brain\/awaa254","article-title":"A road less travelled: the centenary of cisterna magna puncture","volume":"143","author":"Lutters","year":"2020","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2026.06.030_bib56","series-title":"Neuroanatomy, Putamen","author":"Ghandili","year":"2023"},{"key":"10.1016\/j.ymthe.2026.06.030_bib57","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.3390\/jpm12121979","article-title":"Emerging Perspectives on Gene Therapy Delivery for Neurodegenerative and Neuromuscular Disorders","volume":"12","author":"Gomez Limia","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115657","article-title":"Convection-enhanced delivery for brain malignancies: Technical parameters, formulation strategies and clinical perspectives","volume":"224","author":"Parvar","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2026.06.030_bib59","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/mds.30193","article-title":"Intraputaminal Delivery of Adeno-Associated Virus Serotype 2-Glial Cell Line-Derived Neurotrophic Factor in Mild or Moderate Parkinson\u2019s Disease","volume":"40","author":"Van Laar","year":"2025","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2026.06.030_bib60","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1089\/hum.2017.187","article-title":"Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I","volume":"28","author":"Belur","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib61","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ymgme.2012.02.006","article-title":"Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration","volume":"106","author":"Wolf","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2026.06.030_bib62","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s44161-022-00046-4","article-title":"A High-Efficiency AAV for Endothelial Cell Transduction Throughout the Central Nervous System","volume":"1","author":"Krolak","year":"2022","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.ymthe.2026.06.030_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2024.1360302","article-title":"Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria","volume":"4","author":"Haqqani","year":"2024","journal-title":"Front. Drug Deliv."},{"key":"10.1016\/j.ymthe.2026.06.030_bib64","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrd725","article-title":"Drug and gene targeting to the brain with molecular Trojan horses","volume":"1","author":"Pardridge","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.06.030_bib65","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1016\/j.ymthe.2025.04.046","article-title":"Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-brain barrier","volume":"33","author":"Moyer","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib66","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jconrel.2018.03.019","article-title":"A brain targeting functionalized liposomes of the dopamine derivative N-3,4-bis(pivaloyloxy)-dopamine for treatment of Parkinson\u2019s disease","volume":"277","author":"Qu","year":"2018","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2026.06.030_bib67","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1021\/acscentsci.2c00741","article-title":"Brain-Targeted Biomimetic Nanodecoys with Neuroprotective Effects for Precise Therapy of Parkinson\u2019s Disease","volume":"8","author":"Liu","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ymthe.2026.06.030_bib68","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3390\/pharmaceutics14061240","article-title":"Treatment of Neuronopathic Mucopolysaccharidoses with Blood-Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis","volume":"14","author":"Sonoda","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2026.06.030_bib69","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3390\/pharmaceutics14102237","article-title":"Blood-Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles","volume":"14","author":"Thomsen","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2026.06.030_bib70","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20211057","article-title":"Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme","volume":"219","author":"Arguello","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib71","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the Brainshuttle amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","volume":"15","author":"Grimm","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.ymthe.2026.06.030_bib76","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.adm8386","article-title":"An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery","volume":"384","author":"Huang","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.06.030_bib77","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2018.06.006","article-title":"Nanodisk-based glioma-targeted drug delivery enabled by a stable glycopeptide","volume":"284","author":"Wang","year":"2018","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2026.06.030_bib78","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11095-020-02826-8","article-title":"L-Type amino acid transporter 1 as a target for drug delivery","volume":"37","author":"Puris","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ymthe.2026.06.030_bib79","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0006-8993(00)02758-X","article-title":"The 4F2hc\/LAT1 complex transports L-DOPA across the blood-brain barrier","volume":"879","author":"Kageyama","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.ymthe.2026.06.030_bib80","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3892\/ijo.2025.5789","article-title":"Nanoparticle-based delivery systems for targeted therapy in brain tumors: Progress, challenges and perspectives","volume":"67","author":"Si","year":"2025","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib81","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1172\/JCI10498","article-title":"Clearance of Alzheimer\u2019s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier","volume":"106","author":"Shibata","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.06.030_bib82","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202207","article-title":"Endothelial LRP1 protects against neurodegeneration by blocking cyclophilin A","volume":"218","author":"Nikolakopoulou","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib83","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/jcbfm.2015.44","article-title":"Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer\u2019s disease","volume":"36","author":"Halliday","year":"2016","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.ymthe.2026.06.030_bib84","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3390\/ijms26010403","article-title":"Roles of the Receptor for Advanced Glycation End Products and Its Ligands in the Pathogenesis of Alzheimer\u2019s Disease","volume":"26","author":"Li","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.06.030_bib85","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40035-024-00430-z","article-title":"Blood-brain barrier alterations and their impact on Parkinson\u2019s disease pathogenesis and therapy","volume":"13","author":"Lau","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.ymthe.2026.06.030_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111401","article-title":"Interaction of RAGE with alpha-synuclein fibrils mediates inflammatory response of microglia","volume":"40","author":"Long","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.06.030_bib87","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/01.jnen.0000179050.54522.5a","article-title":"Evidence of oxidative stress in the neocortex in incidental Lewy body disease","volume":"64","author":"Dalf\u00f3","year":"2005","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib88","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib89","article-title":"Microenvironment Remodeling Micelles for Alzheimer\u2019s Disease Therapy by Early Modulation of Activated Microglia","volume":"6","author":"Lu","year":"2019","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ymthe.2026.06.030_bib90","doi-asserted-by":"crossref","first-page":"21702","DOI":"10.1021\/jacs.0c08395","article-title":"Self-Protecting Biomimetic Nanozyme for Selective and Synergistic Clearance of Peripheral Amyloid-beta in an Alzheimer\u2019s Disease Model","volume":"142","author":"Ma","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2026.06.030_bib91","first-page":"0180","article-title":"Pathological BBB Crossing Melanin-Like Nanoparticles as Metal-Ion Chelators and Neuroinflammation Regulators against Alzheimer\u2019s Disease","volume":"6","author":"Huang","year":"2023","journal-title":"Research (Wash D C)"},{"key":"10.1016\/j.ymthe.2026.06.030_bib92","article-title":"Ameliorating Mitochondrial Dysfunction of Neurons by Biomimetic Targeting Nanoparticles Mediated Mitochondrial Biogenesis to Boost the Therapy of Parkinson\u2019s Disease","volume":"10","author":"Zheng","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.ymthe.2026.06.030_bib93","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ymthe.2005.11.013","article-title":"Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses","volume":"13","author":"Work","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib94","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/nm.2025","article-title":"Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy","volume":"15","author":"Chen","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib95","doi-asserted-by":"crossref","first-page":"609","DOI":"10.15252\/emmm.201506078","article-title":"A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases","volume":"8","author":"K\u00f6rbelin","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib96","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1177\/0271678X19865917","article-title":"Brain endothelial specific gene therapy improves experimental Sandhoff disease","volume":"40","author":"Dogbevia","year":"2020","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.ymthe.2026.06.030_bib97","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jnc.15621","article-title":"A novel strategy for delivering Niemann-Pick type C2 proteins across the blood-brain barrier using the brain endothelial-specific AAV-BR1 virus","volume":"164","author":"Rasmussen","year":"2023","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymthe.2026.06.030_bib98","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1093\/brain\/awac243","article-title":"Gene therapy targeting the blood-brain barrier improves neurological symptoms in a model of genetic MCT8 deficiency","volume":"145","author":"Sundaram","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2026.06.030_bib99","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1038\/s41467-023-38582-7","article-title":"Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates","volume":"14","author":"Chen","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.030_bib100","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/mt.2010.114","article-title":"Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors","volume":"18","author":"Su","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib137","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: a clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib138","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/gt.2017.14","article-title":"MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain","volume":"24","author":"Samaranch","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib139","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fnana.2019.00093","article-title":"Adeno-Associated Virus Technologies and Methods for Targeted Neuronal Manipulation","volume":"13","author":"Haery","year":"2019","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.ymthe.2026.06.030_bib140","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1073\/pnas.0810682106","article-title":"Efficient gene therapy-based method for the delivery of therapeutics to primate cortex","volume":"106","author":"Kells","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.06.030_bib141","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3390\/ijms21051567","article-title":"BDNF Expression in Cortical GABAergic Interneurons","volume":"21","author":"Tom\u00e1s","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.06.030_bib142","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3390\/jcm9020456","article-title":"GDNF, A Neuron-Derived Factor Upregulated in Glial Cells during Disease","volume":"9","author":"Duarte Azevedo","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib143","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.745159","article-title":"GABAergic Gene Regulatory Elements Used in Adeno-Associated Viral Vectors","volume":"12","author":"Duba-Kiss","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib144","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129240","article-title":"Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging","volume":"4","author":"Mazur","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.06.030_bib145","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.1093\/nar\/gkad371","article-title":"A single-cell map of antisense oligonucleotide activity in the brain","volume":"51","author":"Mortberg","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.06.030_bib147","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau9859","article-title":"Physical positioning markedly enhances brain transduction after intrathecal AAV9 infusion","volume":"4","author":"Castle","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2026.06.030_bib148","article-title":"A Phase I Clinical Trial of AAV2-BDNF Gene Therapy for Alzheimer\u2019s Disease: Findings","volume":"21","author":"Mark","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.ymthe.2026.06.030_bib149","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1212\/WNL.0000000000206690","article-title":"Phase 1b Safety and Preliminary Efficacy of Bilateral Intraputaminal Delivery of AAV2 GDNF (AB-1005) in Participants With Mild or Moderate Parkinson\u2019s Disease (N2.001)","volume":"102","author":"Van Laar","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2026.06.030_bib151","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","article-title":"Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial","volume":"80","author":"Edwards","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib152","author":"Stansfield"},{"key":"10.1016\/j.ymthe.2026.06.030_bib155","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib156","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s40263-021-00878-x","article-title":"Nusinersen: A Review in 5q Spinal Muscular Atrophy","volume":"35","author":"Hoy","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ymthe.2026.06.030_bib159","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.70151","article-title":"Pharmacodynamics, Efficacy, and Safety of Intraputaminal Eladocagene Exuparvovec Administered to Pediatric Patients With Aromatic L-Amino Acid Decarboxylase Deficiency Using an MR-Compatible Cannula: 48 Weeks of Follow-Up","volume":"49","author":"Curry","year":"2026","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2026.06.030_bib160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jamaneurol.2025.4946","article-title":"Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis","volume":"83","author":"Miller","year":"2026","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib163","first-page":"1","article-title":"Atidarsagene Autotemcel (Hematopoietic Stem Cell GeneTherapy) Preserves Cognitive and Motor Development in Metachromatic Leukodystrophy with up to 12 Years Follow-Up. ASGCT 27th Annual Meeting Abstracts; May 3, 2024","volume":"32 suppl. 1","author":"Valeria","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib165","author":"Stansfield"},{"key":"10.1016\/j.ymthe.2026.06.030_bib166","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymthe.2025.09.042","article-title":"Non-neurological, non-skeletal outcomes after hematopoietic stem and progenitor cell-gene therapy (OTL-203) for Hurler syndrome","volume":"34","author":"Tucci","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib167","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14712598.2025.2606047","article-title":"From trial to transformation: insights into hematopoietic stem cell-gene therapy for Hurler syndrome","volume":"25","author":"Tucci","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib168","author":"Stansfield"},{"key":"10.1016\/j.ymthe.2026.06.030_bib170","author":"Bryson"},{"key":"10.1016\/j.ymthe.2026.06.030_bib172","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41434-018-0017-8","article-title":"Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain","volume":"25","author":"Sullivan","year":"2018","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib173","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/brain\/awy126","article-title":"A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency","volume":"141","author":"Tordo","year":"2018","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2026.06.030_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsb.2021.107795","article-title":"Comparative structural, biophysical, and receptor binding study of true type and wild type AAV2","volume":"213","author":"Bennett","year":"2021","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib175","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s12967-023-04208-1","article-title":"Intraparenchymal convection enhanced delivery of AAV in sheep to treat Mucopolysaccharidosis IIIC","volume":"21","author":"O\u2019Leary","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib176","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1128\/JVI.00254-08","article-title":"In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses","volume":"82","author":"Grimm","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib177","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1186\/s12967-024-05599-5","article-title":"AAV-DJ is superior to AAV9 for targeting brain and spinal cord, and de-targeting liver across multiple delivery routes in mice","volume":"22","author":"Chauhan","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib178","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.mt.6300049","article-title":"Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector","volume":"15","author":"Sondhi","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib179","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ymthe.2005.09.003","article-title":"High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses","volume":"13","author":"De","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib180","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.tibs.2024.03.002","article-title":"Computationally guided AAV engineering for enhanced gene delivery","volume":"49","author":"Guo","year":"2024","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ymthe.2026.06.030_bib181","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ymthe.2017.09.006","article-title":"In Vivo Selection of a Computationally Designed SCHEMA AAV Library Yields a Novel Variant for Infection of Adult Neural Stem Cells in the SVZ","volume":"26","author":"Ojala","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib184","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1039\/D2BM00420H","article-title":"Targeted delivery of irinotecan and SLP2 shRNA with GRP-conjugated magnetic graphene oxide for glioblastoma treatment","volume":"10","author":"Chuang","year":"2022","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ymthe.2026.06.030_bib185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12987-025-00641-0","article-title":"PepH3-modified nanocarriers for delivery of therapeutics across the blood-brain barrier","volume":"22","author":"Szecsk\u00f3","year":"2025","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.ymthe.2026.06.030_bib186","doi-asserted-by":"crossref","first-page":"81001","DOI":"10.18632\/oncotarget.20944","article-title":"PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Abeta generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer\u2019s disease mice","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2026.06.030_bib187","article-title":"Brain-Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha-Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson\u2019s Disease","volume":"35","author":"Sela","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ymthe.2026.06.030_bib188","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.3390\/nano13192697","article-title":"Polyoxometalate-Decorated Gold Nanoparticles Inhibit beta-Amyloid Aggregation and Cross the Blood-Brain Barrier in a microphysiological Model","volume":"13","author":"Perxes","year":"2023","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.ymthe.2026.06.030_bib189","article-title":"Brain Delivery of Protein Therapeutics by Cell Matrix-Inspired Biomimetic Nanocarrier","volume":"36","author":"Huang","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ymthe.2026.06.030_bib190","doi-asserted-by":"crossref","first-page":"11015","DOI":"10.2147\/IJN.S549893","article-title":"Nanotechnology for Neurodegenerative Diseases: Recent Progress in Brain-Targeted Delivery, Stimuli-Responsive Platforms, and Organelle-Specific Therapeutics","volume":"20","author":"Gao","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ymthe.2026.06.030_bib191","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006839","article-title":"Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma","volume":"5","author":"Jensen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib192","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil(R)--the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2026.06.030_bib193","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3390\/ijms26051814","article-title":"Nanotherapy of Glioblastoma-Where Hope Grows","volume":"26","author":"Grzegorzewski","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.06.030_bib194","article-title":"The landscape of nanomedical clinical trials","volume":"66","author":"Evin","year":"2026","journal-title":"Nano Today"},{"key":"10.1016\/j.ymthe.2026.06.030_bib195","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202502315","article-title":"Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape","volume":"21","author":"Desai","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.ymthe.2026.06.030_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.146832","article-title":"Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies","volume":"1739","author":"Bailey","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.ymthe.2026.06.030_bib197","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/ijnp\/pyad028","article-title":"Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia","volume":"26","author":"Najarian","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib198","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s40263-014-0180-4","volume":"28","author":"Ginsberg","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ymthe.2026.06.030_bib200","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3945","article-title":"A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma","volume":"13","author":"Kumthekar","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib201","first-page":"637","article-title":"Histology of Cerebral Lesions Produced by Focused Ultrasound","volume":"20","author":"Lynn","year":"1944","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib202","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1109\/IRET-ME.1960.5008041","article-title":"Fundamental neurological research and human neurosurgery using intense ultrasound","volume":"ME-7","author":"Fry","year":"1960","journal-title":"IRE Trans. Med. Electron."},{"key":"10.1016\/j.ymthe.2026.06.030_bib203","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.addr.2014.01.008","article-title":"Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system","volume":"72","author":"Aryal","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2026.06.030_bib204","doi-asserted-by":"crossref","DOI":"10.3389\/fphy.2022.791145","article-title":"Ultrasound Contrast Imaging: Fundamentals and Emerging Technology","volume":"10","author":"Yusefi","year":"2022","journal-title":"Front. Phys."},{"key":"10.1016\/j.ymthe.2026.06.030_bib205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0271678X211046129","article-title":"A review of bioeffects induced by focused ultrasound combined with microbubbles on the neurovascular unit","volume":"42","author":"Chen","year":"2022","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.ymthe.2026.06.030_bib206","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1148\/radiol.2202001804","article-title":"Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits","volume":"220","author":"Hynynen","year":"2001","journal-title":"Radiology"},{"key":"10.1016\/j.ymthe.2026.06.030_bib207","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.expneurol.2011.10.027","article-title":"Targeted gene delivery to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption","volume":"233","author":"Huang","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib208","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1089\/hum.2012.013","article-title":"Targeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasound","volume":"23","author":"Thevenot","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib209","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf4888","article-title":"BBB opening with focused ultrasound in nonhuman primates and Parkinson\u2019s disease patients: Targeted AAV vector delivery and PET imaging","volume":"9","author":"Blesa","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2026.06.030_bib210","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(25)00492-9","article-title":"Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1\/2 trial","volume":"26","author":"Woodworth","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2026.06.030_bib211","author":"Davis"},{"key":"10.1016\/j.ymthe.2026.06.030_bib213","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41467-021-21022-9","article-title":"Blood-brain barrier opening with focused ultrasound in Parkinson\u2019s disease dementia","volume":"12","author":"Gasca-Salas","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.030_bib214","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.3390\/pharmaceutics14122607","article-title":"Cavitation Feedback Control of Focused Ultrasound Blood-Brain Barrier Opening for Drug Delivery in Patients with Parkinson\u2019s Disease","volume":"14","author":"Huang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2026.06.030_bib215","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/brain\/awac459","article-title":"Blood-brain barrier opening of the default mode network in Alzheimer\u2019s disease with magnetic resonance-guided focused ultrasound","volume":"146","author":"Meng","year":"2023","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2026.06.030_bib216","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMoa2308719","article-title":"Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer\u2019s Disease","volume":"390","author":"Rezai","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib217","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.7150\/thno.94206","article-title":"Transcranial blood-brain barrier opening in Alzheimer\u2019s disease patients using a portable focused ultrasound system with real-time 2-D cavitation mapping","volume":"14","author":"Bae","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.ymthe.2026.06.030_bib219","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3390\/pharmaceutics13122024","article-title":"Modulation of the Blood-Brain Barrier for Drug Delivery to Brain","volume":"13","author":"Han","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2026.06.030_bib220","article-title":"Safety of intra-arterial chemotherapy with or without osmotic blood-brain barrier disruption for the treatment of patients with brain tumors","volume":"4","author":"Uluc","year":"2022","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.ymthe.2026.06.030_bib221","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021915118","article-title":"Blood-brain barrier opening by intracarotid artery hyperosmolar mannitol induces sterile inflammatory and innate immune responses","volume":"118","author":"Burks","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.06.030_bib222","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/nyas.13359","article-title":"Claudin peptidomimetics modulate tissue barriers for enhanced drug delivery","volume":"1397","author":"Dithmer","year":"2017","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ymthe.2026.06.030_bib223","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2018.05.010","article-title":"Angubindin-1 opens the blood-brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system","volume":"283","author":"Zeniya","year":"2018","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2026.06.030_bib224","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41467-017-00952-3","article-title":"Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain","volume":"8","author":"Anraku","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.06.030_bib225","article-title":"Blood-brain barrier disruption following MR-guided laser interstitial thermal therapy","volume":"7","author":"Nielsen","year":"2025","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.ymthe.2026.06.030_bib226","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/CJI.0000000000000485","article-title":"Laser Interstitial Thermal Therapy Induces Robust Local Immune Response for Newly Diagnosed Glioblastoma With Long-term Survival and Disease Control","volume":"46","author":"Chandar","year":"2023","journal-title":"J. Immunother."},{"key":"10.1016\/j.ymthe.2026.06.030_bib227","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.omtm.2020.10.011","article-title":"CNS Transduction Benefits of AAV-PHP.eB over AAV9 Are Dependent on Administration Route and Mouse Strain","volume":"19","author":"Mathiesen","year":"2020","journal-title":"Mol. Ther. - Methods Clin. Development"},{"key":"10.1016\/j.ymthe.2026.06.030_bib228","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.ymthe.2019.07.017","article-title":"AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice","volume":"27","author":"Liguore","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib229","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/hum.2017.037","article-title":"Retro-Orbital Venous Sinus Delivery of rAAV9 Mediates High-Level Transduction of Brain and Retina Compared with Temporal Vein Delivery in Neonatal Mouse Pups","volume":"28","author":"Gruntman","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib230","article-title":"Nanoparticle distribution in the central nervous system following intrathecal administration: A multi-modal analysis of lumbar versus cisterna magna routes","volume":"71","author":"Babayemi","year":"2026","journal-title":"Nanomedicine: Nanotechnology, Biol. Med."},{"key":"10.1016\/j.ymthe.2026.06.030_bib231","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100416","article-title":"Antisense technology: A review","volume":"296","author":"Crooke","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.06.030_bib232","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jconrel.2021.06.009","article-title":"Safety and efficacy of an anti-claudin-5 monoclonal antibody to increase blood-brain barrier permeability for drug delivery to the brain in a non-human primate","volume":"336","author":"Tachibana","year":"2021","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2026.06.030_bib233","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40824-022-00292-4","article-title":"Nonviral delivery systems for antisense oligonucleotide therapeutics","volume":"26","author":"Huang","year":"2022","journal-title":"Biomater. Res."},{"key":"10.1016\/j.ymthe.2026.06.030_bib234","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41434-025-00512-1","article-title":"Safety, efficacy, and immunogenicity of a novel IgG degrading enzyme (KJ103): results from two randomised, blinded, phase 1 clinical trials","volume":"32","author":"Cao","year":"2025","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib235","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.omtm.2019.07.003","article-title":"Site-Specific Glycation and Chemo-enzymatic Antibody Sortagging for the Retargeting of rAAV6 to Inflamed Endothelium","volume":"14","author":"Pearce","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.06.030_bib236","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41434-025-00570-5","article-title":"Antibody-guided AAV vectors for antigen-specific delivery of suicide genes","volume":"33","author":"Inano","year":"2026","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.06.030_bib237","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104277","article-title":"Incisionless targeted adeno-associated viral vector delivery to the brain by focused ultrasound-mediated intranasal administration","volume":"84","author":"Ye","year":"2022","journal-title":"EBioMedicine"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626005071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626005071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:19:56Z","timestamp":1788362396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626005071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":181,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1525001626005071"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.06.030","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene delivery for cerebral neurodegenerative disorders: Current advancements and limitations","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}